Ostrich Pharma USA Produces Antibodies to Block the Virus that Causes COVID-19
Retrieved on:
Tuesday, March 31, 2020
Ostrich Pharma USA has announced the successful development of ostrich antibodies to the SARS-CoV-2 virus, the expanding use of those antibodies in Japan, and plans for producing and deploying the antibodies in the U.S.
Key Points:
- Ostrich Pharma USA has announced the successful development of ostrich antibodies to the SARS-CoV-2 virus, the expanding use of those antibodies in Japan, and plans for producing and deploying the antibodies in the U.S.
Dr. Yasuhiro Tsukamoto, Dean of the Graduate School of Life and Environmental Sciences at Kyoto Prefectural University and Co-CEO of Ostrich Pharma USA, has injected a genetically engineered pseudovirus into ostriches, and antibodies were purified from their eggs. - We were even more pleased to see how capable the antibodies were in blocking the virus that causes COVID-19.
- Ten ostriches have been vaccinated, and the antibodies from their eggs have already been used in masks, nasal drops, and candies in Japan.
- According to Ostrich Pharma USA Co-CEO Stuart Greenberg, We recognize the enormous need for multiple approaches to the COVID-19 pandemic in the US.